Evidence map›Paper›PMID 33023264›Full record

ReviewInternational journal of molecular sciences2020

Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment.

Kamila Raziyeva, Aiganym Smagulova, Yevgeniy Kim, Saltanat Smagul, Ayan Nurkesh, Arman Saparov

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 65 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kamila RaziyevaDepartment of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan.
Aiganym SmagulovaDepartment of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan.
Yevgeniy KimDepartment of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan.
Saltanat SmagulDepartment of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan.
Ayan NurkeshDepartment of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan.
Arman SaparovDepartment of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan.ORCID 0000-0002-4407-1236
Nazarbayev University · KZ

Funding

Ministry of Education and Science of the Republic of Kazakhstan AP05135207
6 · The paper itself

Abstract

Ischemic heart disease and myocardial infarction remain leading causes of mortality worldwide. Existing myocardial infarction treatments are incapable of fully repairing and regenerating the infarcted myocardium. Stem cell transplantation therapy has demonstrated promising results in improving heart function following myocardial infarction. However, poor cell survival and low engraftment at the harsh and hostile environment at the site of infarction limit the regeneration potential of stem cells. Preconditioning with various physical and chemical factors, as well as genetic modification and cellular reprogramming, are strategies that could potentially optimize stem cell transplantation therapy for clinical application. In this review, we discuss the most up-to-date findings related to utilizing preconditioned stem cells for myocardial infarction treatment, focusing mainly on preconditioning with hypoxia, growth factors, drugs, and biological agents. Furthermore, genetic manipulations on stem cells, such as the overexpression of specific proteins, regulation of microRNAs, and cellular reprogramming to improve their efficiency in myocardial infarction treatment, are discussed as well.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsApoptosisHumansMesenchymal Stem CellsMyocardial InfarctionMyocardiumRegenerationSignal Transductioncell reprogramminggenetic modificationmyocardial infarctionstem cell differentiationstem cell preconditioningstem cell therapy

Identifiers

PMID33023264
PMCPMC7582407
OpenAlexW3090573230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.